Skip to content
  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
Daily News India

Daily News India

Just another WordPress site

  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
  • Toggle search form
  • Praveg Limited Announces Strategic Inventory Agreement with Mahindra Holidays and Resorts India Limited for Praveg Atoll, Lakshadweep – Thinnakkara Business
  • Asim Riaz – Sandeepa Dhar starrer AB Bansal Music’s song ‘Ab Kise Barbaad Karoge’ released Entertainment
  • 10 Emerging Indian Startups in 2023 making big difference Business
  • Ram Path lighting in Ayodhya by Instapower National
  • OTTplay enters into streaming, launches 5 OTT Subscription Packs partnering with 12 Indian & International OTTs, launches 4 International OTTs in India for the first time ever! Business
  • Agrowise Launches Comprehensive Agriculture Consultancy to Strengthen Agri-Businesses and Promote Public Health Business
  • From Three Days of Chaos to Five Minutes of Done: The New Way India Moves Business
  • JeetWin Partners with Nidhhi Agerwal as Brand Ambassador to Strengthen Gaming Platform’s Reach Entertainment

ISSAR Pharma Announces Out-Licensing of Its Peptide-Based NCEs

Posted on April 29, 2021 By

ISSAR Pharma, the only company in India which focuses on the research and development of New Chemical Entities (NCE), is licensing out its NCEs based on peptide technology, opening opportunities for fruitful partnerships.

Hyderabad (Telangana) [India], April 29: ISSAR Pharmaceuticals, the Pioneer in Peptide Technology and peptide drug innovation, has decided to license out their peptide-based New Chemical Entities (NCEs), with pre-IND filing and US Patent. The potential collaboration would help ISSAR Pharmaceuticals in their goal to design and deliver novel peptide-based drugs for various unmet healthcare needs of the population and making them affordable and accessible for better health outcomes.

ISSAR Pharmaceuticals exclusively focuses on peptide technology-based research and development of New Chemical Entities (NCE) for various unmet medical needs to improve the quality of life. ISSAR uses Solid-phase peptide synthesis as the technology of choice and has the capability to synthesize custom peptides, API peptides, and cosmetic peptides at all scales within a short duration. With an emphasis on quality, safety, and innovation, ISSAR has demonstrated the ability to move products from conceptualisation to commercialisation of peptide molecules at all stages. ISSAR has several patents for potential life-changing peptide molecules lined up in their development pipeline targeting therapeutic areas such as oncology, dermatology, gastroenterology, and diseases of bones and joints.

“We take pride in being India’s first-ever company to conduct phase-1 clinical trials and launch the first-ever indigenous peptide drug, Melgain in the market for the treatment of Vitiligo in 2004”, informs Mr. Ramakrishna Reddy Isanaka, the founder of ISSAR. ISSAR’s

FDA- compliant state-of-the-art manufacturing facility of 62000 sq. ft., is purely into peptide manufacturing technology, located in Genome Valley, Hyderabad, India. In addition to its experience in R&D, ISSAR is equipped with the most advanced and automatic technology with expertise in the synthesis and purification of peptides, producing the highest standards of purity of up to 99.5% by continued process optimization.

With over 25 years of experience and a prime focus in Research and Development, ISSAR’s dedicated team of experts is proud to have developed India’s first-ever peptide molecule, Melgain for the treatment of Vitiligo in 2004, which is now introduced as Novoskin® with improved properties and effectiveness. ISSAR’s commitment has also led to the development of their second New Chemical Entity called Xylentra, which is the first-ever peptide drug in the world for the treatment of burn wounds and microbial infections.

ISSAR developed molecules for prevalent conditions in the Western world such as Inflammatory Bowel Diseases (IBD), Psoriasis, and Sepsis. Recently, an NCE for the treatment of burn wounds (Xylentra) was licensed to Viatris, formerly known as Mylan Laboratories, the USA in 2020.

ISSAR Pharmaceuticals was founded by Mr. Ramakrishna Reddy Isanaka in 1995 with a vision to be a global leader in peptide drug discovery for improving patients’ quality of life. Before starting ISSAR Pharmaceutical, Mr.Isanaka was the promoter and director of Shantha Biotechnics in the 1980s, at a time when Biotechnology was new to India.

His efforts in research and development led to the advancement of ISSAR Pharma as the first-ever company in India to conduct Phase-I Clinical Trials in the year 1995. Today, he has over 25 years of experience in the development of NCEs with 2 successfully commercialized products, 7 plus patents to his credit, and over 6 commercially viable products under development.

https://issar.co.in/

English, Health, Press Release Tags:ISSARPharma, PeptidebasedNCEs, PNN

Post navigation

Previous Post: Glimpse up the world @worldwithmaria
Next Post: Indian Furniture Rental Industry – Market Size, Growth & Scope

Related Posts

  • Revolutionizing Minimally Invasive Surgery for Gallbladder Cancer and Enhancing Recovery and Survival Rates: Dr. Vipulroy Rathore Health
  • Environmentalist Viral Desai will develop a school as a model green school in Surat Press Release
  • Incredible! 5 years old Kritika Tripathi creates history by securing major world records in Thaiboxing Press Release
  • Dr. Garima Mehta’s Ultimate Guide to Screen Time in 2025 for Parents Health
  • Immigration Advisory Company, IIA Soon To Launch New Offices In Metropolitan Cities Press Release
  • Statue Grooming by Wild Stone: Great Men Deserve To Look Great Press Release

Recent Posts

  • Cashless Garage Network Check: Why It Matters for High-Mileage Drivers
  • Western Overseas Study Abroad Limited Reports H1 FY27 Performance Update Total Income Stands at Rs 747.76 Lakhs, with PAT of Rs 53.89 Lakhs
  • mastertrust Introduces mtAlgoZ, Strengthening Its Digital Trading Platform with Automated Strategy Building and Execution
  • Anlon Technology Solutions Limited Reports Q2 & H1 FY27 Results; Q2 Total Income Up 184%, EBITDA Up 216% and Net Profit Up 231% YoY
  • Kellton launches KeOS to help enterprises govern AI agents in production

Recent Comments

  • Unknown on Participants Reap Rewards in Wellman’s 8-Week Digital Campaign: IPL Tickets, Autographed Virat Kohli Merchandise, and More!
  • Hindi Film Neera Arya’s Motion Poster Launched in Delhi by Netaji Subhash Chandra Bose’s Great Grand Daughter Rajshree Bose Business
  • AsthaTrade empowers stock traders by making Equity Intraday brokerage FREE Business
  • 12 Exceptional Individuals Making a Difference In 2026 Lifestyle
  • IAMAI Summit Highlights ISEC’s Prominence in Digital World with Yashwant Deshmukh Business
  • JAIN (Deemed-to-be University) Introduces Generative AI Certification for BCA IT for Healthcare Students, Powering the Next Wave of Digital Healthcare Leaders Education
  • Mumbai Flatmates Go Viral for Calling a Service Just to Fill Water Bottles Entertainment
  • Sampre Nutritions Ltd has entered into a Manufacturing Agreement with Reliance Consumer Products Ltd Business
  • How Golden Oakk Infotech Went from Chasing Failed Payments to a 98% Success Rate with Paywize Business

Copyright © 2026 Daily News India.

Powered by PressBook News WordPress theme